📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Amrutanjan Q3 FY26 Net Sales Up 14.9% to ₹141 Cr; YTD PAT Grows 17% YoY
Amrutanjan Health Care reported a 14.9% YoY increase in Q3 FY26 net sales to ₹141.04 crore, supported by strong performance in the OTC and Comfy segments. While Q3 PAT growth was nearly flat at 1.04% due to higher operational expenses, the nine-month (YTD) performance remains robust with PAT rising 17.02% to ₹41.73 crore. The company is aggressively expanding its distribution, adding 40,000 new chemist outlets and launching premium products like Comfy Night Pads to drive future growth.
Key Highlights
Q3 FY26 Net Sales grew 14.9% YoY to ₹141.04 Cr, while YTD Dec'25 PAT rose 17.02% to ₹41.73 Cr.
The Comfy (Women's Hygiene) brand recorded a strong 22.55% Net Sales growth in Q3 FY26.
Operational efficiency improved significantly with total lines sold increasing by 73% and effective outlet coverage up 10%.
The company added 40,000 new chemist outlets, progressing toward its long-term goal of 100,000 additional outlets.
Pain Management segment maintained momentum with 12% YTD growth, led by a 27% growth in Head Roll-On variants.
💼 Action for Investors
Investors should focus on the company's successful diversification into Women's Hygiene and its distribution expansion, which are offsetting the decline in the Rehydration segment. The strong YTD profit growth suggests healthy underlying business momentum despite a high-base effect in Q3 quarterly profits.
Amrutanjan Health Care Sets Feb 7, 2026, as Record Date for Second Interim Dividend
Amrutanjan Health Care Limited has officially fixed February 7, 2026, as the record date for its second interim dividend for the financial year 2025-26. This announcement follows the company's compliance with Regulation 42 of SEBI (LODR) Regulations 2015. Shareholders whose names appear in the register of members or as beneficial owners with NSDL and CDSL on the record date will be eligible for the payout. This marks the second dividend distribution for the current fiscal year, reflecting continued shareholder returns.
Key Highlights
Record date for the Second Interim Dividend is fixed as February 07, 2026
The dividend distribution pertains to the financial year 2025-26
Eligibility is based on beneficial ownership data from NSDL and CDSL as of the record date
Official notification was released on February 03, 2026, following regulatory requirements
💼 Action for Investors
Investors seeking to qualify for the dividend should ensure they purchase or hold the shares before the ex-dividend date. Long-term investors should track the total dividend yield for FY26 as part of their income strategy.
Amrutanjan Q3 Net Profit at ₹19.45 Cr; Declares Re. 1 Interim Dividend
Amrutanjan Health Care reported a steady performance for Q3 FY26 with revenue from operations growing 14.9% YoY to ₹141.04 crore. The company declared its second interim dividend of Re. 1 per share for the financial year 2025-26. While net profit saw a marginal increase to ₹19.45 crore, it was slightly impacted by a ₹1.25 crore exceptional charge related to new labour codes. The core OTC and Women's Hygiene segments showed robust growth, while the Beverages segment faced a decline in revenue.
Key Highlights
Declared second interim dividend of Re. 1 per equity share (100% of face value)
Q3 Revenue from operations increased 14.9% YoY to ₹141.04 crore
Net Profit for the quarter stood at ₹19.45 crore versus ₹19.25 crore in the previous year
OTC segment revenue grew 14.3% YoY to ₹100.54 crore, remaining the primary growth driver
Recognized an exceptional item of ₹125.17 lakhs due to the impact of new Labour Codes
💼 Action for Investors
Investors should find comfort in the steady growth of the core OTC and Women's Hygiene segments and the consistent dividend payout. The stock remains a stable play in the healthcare and consumer goods space with a strong focus on governance as reflected in its high ESG governance score.
Amrutanjan Q3 Revenue Up 14.9% to ₹141 Cr; Declares ₹1 Interim Dividend
Amrutanjan Health Care reported a 14.9% YoY increase in revenue from operations to ₹141.04 crore for the quarter ended December 31, 2025. Net profit remained relatively flat at ₹19.45 crore compared to ₹19.25 crore in the previous year, primarily due to a ₹1.25 crore exceptional item related to new labor codes. The company declared a second interim dividend of ₹1 per share. Notably, the Women's Hygiene segment showed strong growth, contributing ₹36.68 crore to the top line.
Key Highlights
Revenue from operations grew 14.9% YoY to ₹14,103.87 Lakhs from ₹12,275.15 Lakhs.
Profit After Tax (PAT) stood at ₹1,945.22 Lakhs, up 1.1% YoY despite an exceptional cost.
Declared a second interim dividend of ₹1 per equity share for the financial year 2025-26.
Women's Hygiene segment revenue increased 22.6% YoY to ₹3,667.97 Lakhs.
Recognized an exceptional expense of ₹125.17 Lakhs due to the impact of new labor codes on gratuity and leave encashment.
💼 Action for Investors
Investors should take note of the robust top-line growth and the successful scaling of the Women's Hygiene business. The flat net profit is a result of non-recurring regulatory costs, suggesting healthy underlying operational efficiency.